SAN DIEGO, July 1, 2015 /PRNewswire/ -- AVACEN, Inc. announced today the issue by the US Patent Office of a second AVACEN patent covering the medical technology platform supporting its unique Dry Heat Therapy AVACEN 100 product.
The apparatus and methods patent no. 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal Energy shields certain medical devices manufactured by AVACEN and specific methods of use, referred to by the company as the AVACEN Treatment Method.
The patent consists of 20 claims related to innovations introduced in AVACEN's medical technology that allow multiple therapeutic uses to alleviate a symptom associated with a circulatory, neurological, lymphatic, or endocrinal dysfunction, or any combination thereof.
"This further protects AVACEN's multi-million dollar investment in developing the AVACEN Treatment Method and our first commercial product, the AVACEN 100, which is designed for sufferers of pain related to arthritis and fibromyalgia*," said Thomas G. Muehlbauer, Chairman and CEO, AVACEN Medical.
In January of 2015 AVACEN Medical filed a De Novo application with the FDA to approve its marketing of the AVACEN 100 to sufferers of fibromyalgia.
Fibromyalgia is a complex chronic pain disorder that affects an estimated 10 million Americans. For those with severe symptoms, fibromyalgia can be extremely debilitating and interfere with basic daily activities. "Patent approvals of the AVACEN Treatment Method along with our encouraging Fibromyalgia Clinical Study and anecdotal results are giant steps forward when it comes to commercializing our intellectual property to relieve the pain associated with this terrible disease," added Mr. Muehlbauer.
About the AVACEN 100: In March of 2014 the US Patent Office issued Patent No. 8,679,170 to AVACEN covering key aspects of their medical technology platform and in August of 2014 the FDA cleared the AVACEN 100 as a Class II medical device for the temporary relief of joint pain associated with arthritis; muscle spasms; minor strains and sprains; and muscular relaxation.
About AVACEN: AVACEN Medical is dedicated to the innovation and design of safe, easy to use, noninvasive drug free alternatives to treat pain associated with diseases such as arthritis, fibromyalgia and migraines.
Contact: Ryan Jeffcoat at (888) 4-AVACEN x 711 or Email.
* The AVACEN 100 is pending approval for widespread pain related to fibromyalgia at the U.S. FDA and is not available for sale in the U.S. or globally for that indication.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avacen-medical-patent-issued-300107459.html
SOURCE AVACEN, Inc.